Adjustment in the clinical practice of treat-to-target guidelines for rheumatoid arthritis: Results of the ToARCan study

被引:1
|
作者
Naranjo, Antonio [1 ,2 ]
Caceres, Laura [1 ,2 ]
Hernandez-Beriain, Jose Angel [3 ,5 ]
Francisco, Felix [1 ,2 ]
Ojeda, Soledad [1 ,2 ]
Talaverano, Sigrid
Novoa-Medina, Javier [5 ]
Adan Martin, Jose [4 ]
Delgado, Esmeralda
Trujillo, Elisa
Alvarez, Ftima
Magdalena, Laura
Rodriguez-Lozano, Carlos [1 ,2 ,6 ]
机构
[1] Hosp Univ Gran Canaria Dr Negrin, Serv Reumatol, Gran Canaria, Spain
[2] Univ Las Palmas Gran Canaria, Gran Canaria, Spain
[3] Complejo Hosp Univ Materno Insular Gran Canaria, Serv Reumatol, Gran Canaria, Spain
[4] Hosp Dr Molina Orosa, Serv Reumatol, Molina Orosa, Lanzarote, Spain
[5] Hosp Univ Canarias, Serv Reumatol, Tenerife, Spain
[6] Hosp Univ Nuestra Senora Candelaria, Serv Reumatol, Tenerife, Spain
来源
REUMATOLOGIA CLINICA | 2016年 / 12卷 / 01期
关键词
Rheumatoid arthritis; Treat-to-target; Health care quality; Adherence; DAS28; quality indicators;
D O I
10.1016/j.reuma.2015.03.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective:To analyze compliance with t2t clinical practice guidelines. Methods:Cross-sectional observational study in consecutive patients with rheumatoid arthritis (RA) in 5 hospitals in the Canary Islands. Patients filled out activity scales, HAQ and answered the question of whether the doctor had explained the treatment target. The rheumatologist also collected: visits in the past year, use of activity indices and HAQ, DAS28 of current visit and date of the next visit. The percentage of compliance to indicators based on the t2t recommendations (R) 1, 3, 5-7 and 10 was analyzed. Results:A total of 343 patients were recruited, 77% female, mean age 57, RA duration of 10 years. Median visits in the last year were 3 and mean time between last and current visit was 5.6 months. A total of 93% of the patients were treated with DMARDs and 44% were in remission by DAS (R1). In the previous visit, documented joint count was present in 85%, a HAQ in 19%, patient VAS in 41%, and a DAS28 in 35% of the patients (R6). The next visit was scheduled at an average of 4.3 months (R5). In 64% of patients with DAS28> 3.2 a visit between one and 3 months was scheduled (R5). A total of 96% of patients said they had been informed of the treatment target (R10). Variability between centers existed but was moderate. The only factor determining the performance of a DAS28 in the last visit was the patient's center of origin. Conclusion:The Canary Island centers studied achieved high levels of remission and low activity in their patients. The performance of composite indices and follow-up frequency recommended by the t2t are met, although there is room for improvement. (C) 2014 Elsevier Espana, S.L.U.y Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.
引用
收藏
页码:34 / 38
页数:5
相关论文
共 50 条
  • [21] Psoriatic arthritis: treat-to-target
    Kavanaugh, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (04) : S123 - S125
  • [22] Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
    Marloes Vermeer
    Hillechiena H Kuper
    Hein J Bernelot Moens
    Monique Hoekstra
    Marcel D Posthumus
    Piet LCM van Riel
    Mart AFJ van de Laar
    Arthritis Research & Therapy, 14
  • [23] Psoriatic arthritis: is it time to treat-to-target or target to treat?
    Lubrano, Ennio
    Perrotta, Fabio Massimo
    CLINICAL RHEUMATOLOGY, 2017, 36 (12) : 2633 - 2635
  • [24] Psoriatic arthritis: is it time to treat-to-target or target to treat?
    Ennio Lubrano
    Fabio Massimo Perrotta
    Clinical Rheumatology, 2017, 36 : 2633 - 2635
  • [25] Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
    Vermeer, Marloes
    Kuper, Hillechiena H.
    Moens, Hein J. Bernelot
    Hoekstra, Monique
    Posthumus, Marcel D.
    van Riel, Piet L. C. M.
    van de Laar, Mart A. F. J.
    ARTHRITIS RESEARCH & THERAPY, 2012, 14 (06)
  • [26] TREAT-TO-TARGET IS FEASIBLE IN RHEUMATOID ARTHRITIS PATIENTS DURING PREGNANCY, FIRST RESULTS OF THE PRECARA COHORT
    Smeele, H. T.
    Roder, E.
    Wintjes, H.
    Kranenburg-van Koppen, L. J.
    Hazes, J.
    Dolhain, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1885 - 1886
  • [27] PREDICTORS OF CLINICAL AND IMAGING REMISSION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS MANAGED WITH A TREAT-TO-TARGET APPROACH: RESULTS FROM AN EARLY ARTHRITIS CLINIC
    Horton, Sarah C.
    Tan, Ai Lyn
    Wakefield, Richard J.
    Freeston, Jane E.
    Buch, Maya H.
    Emery, Paul
    RHEUMATOLOGY, 2015, 54 : 76 - 76
  • [28] Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative Results of a Randomized Controlled Trial
    Solomon, Daniel H.
    Losina, Elena
    Lu, Bing
    Zak, Agnes
    Corrigan, Cassandra
    Lee, Sara B.
    Agosti, Jenifer
    Bitton, Asaf
    Harrold, Leslie R.
    Pincus, Theodore
    Radner, Helga
    Yu, Zhi
    Smolen, Josef S.
    Fraenkel, Liana
    Katz, Jeffrey N.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (07) : 1374 - 1380
  • [29] Predictors of satisfactory improvements in pain for patients with early rheumatoid arthritis in a treat-to-target study
    ten Klooster, Peter M.
    Vonkeman, Harald E.
    Voshaar, Martijn A. H. Oude
    Siemons, Liseth
    van Riel, Piet L. C. M.
    van de Laar, Mart A. F. J.
    RHEUMATOLOGY, 2015, 54 (06) : 1080 - 1086
  • [30] Implementation of the Treat-to-Target Approach in Psoriatic Arthritis and Its Outcomes in Routine Clinical Practice
    Din, Shamas U.
    Saeed, Muhammad Ahmed
    Hameed, Muhammad R.
    Aamer, Maryam
    Arshad, Umbreen
    Qamar, Hafiz Yasir
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)